2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1875

Can Allopurinol Survival Impact Reverse Depending on Patients’ Characteristics? a Propensity-Score-Based Subgroup Analysis
Abstract Number: 1868

Can DAS 28 at 3 Months after the 1^st Biologic Therapy Predict Subsequent Sustainable Clinical Remission in Polyarticular Juvenile Idiopathic Arthritis Patients?
Abstract Number: 402

Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis?
Abstract Number: 3007

Can Knee Pain be Prevented through Diet and Exercise Among Those at High Risk? the Look Ahead Study
Abstract Number: 1490

Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers
Abstract Number: 138

Can Ultrasonography of Peripheral Entheses Play a Role in the Diagnosis and Understanding of Diffuse Idiopathic Skeletal Hyperostosis (DISH)?
Abstract Number: 157

Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis
Abstract Number: 1097

Can We Help Identify Learning Disabilities in Fibromyalgia Patients?
Abstract Number: 120

Can We Use Ultrasound to Identify Rheumatoid Arthritis Patients in Remission Who Cannot Taper Their Medication?
Abstract Number: 2291

Canakinumab in Biologic-naïve Versus Previously Biologic-Exposed Systemic Juvenile Idiopathic Arthritis Patients: Efficacy Results from a 12 Week Pooled Post Hoc Analysis
Abstract Number: 159

Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-Steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up
Abstract Number: 1232

Canakinumab Therapy in Patients with Familial Mediterranean Fever
Abstract Number: 2298

Canakinumab Treatment Shows Maintained Efficacy in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Individual Patient Level: An Analysis of 12 Week Pooled Data
Abstract Number: 833

Canakinumab Use in Patients with Cryopyrin-Associated Periodic Syndrome: Interim Safety and Efficacy Results from Beta-Confident Registry
Abstract Number: 853

Cancer Incidence in TNF Inhibitor Treated Patients with Axial Spondyloarthritis and Psoriatic Arthritis – a Study from the ARTIS and Danbio Registers

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].